UK firm GSK to pay $2.2bn over Zantac cancer claimsGSK is settling $2.2bn over Zantac cancer claims, resolving 93% of lawsuits without admitting wrongdoing.
Protecting Pharmaceutical Innovation in Brazil Despite the Lack of a Patent Linkage SystemLitigation remains a viable strategy for ensuring market exclusivity despite limitations from the Bolar Exemption.
More Than 900 Patients Say Ozempic and Similar Drugs Unexpectedly Injured ThemOver 900 individuals are suing drugmakers, claiming GLP-1 drugs like Ozempic caused severe gastrointestinal injuries, even after stopping usage.